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A B S T R A C T
French and American guidelines recommend increased dosage regimens of cefazolin (CFZ) for surgical
prophylaxis in patients with a bodymass index (BMI) ≥ 35 kg/m2 or with a total bodyweight (TBW) ≥ 120 kg.
The objective of this study was to evaluate the accuracy of these cut-offs in identifying patients who require
CFZ dose adjustment. A pharmacokinetic study was conducted in patients of varying TBW and BMI who
received 2 g of CFZ intravenously for prophylaxis prior to digestive surgery. Adequacy of therapy, deﬁned
as a serum concentration of unbound CFZ (fCFZ) ≥ 4mg/L, was evaluated 180min (T180) and 240min (T240)
after the start of CFZ infusion. Possible factors associated with insuﬃcient fCFZ levels were also as-
sessed. A P-value of <0.05 was considered statistically signiﬁcant. A total of 63 patients were included
in the study, categorised according to BMI (<35 kg/m2, 20 patients; and ≥35 kg/m2, 43 patients) and TBW
(<120 kg, 41 patients; and ≥120 kg, 22 patients). All patients had adequate drug levels at T180 but only
40/63 patients (63%) had adequate levels at T240. At T240, therapy was adequate in 15/20 patients (75%)
and 25/43 patients (58%) with BMI <35 kg/m2 and ≥35 kg/m2, respectively (P = 0.20), and in 28/41 pa-
tients (68%) and 12/22 patients (55%) with TBW <120 kg and ≥120 kg, respectively (P = 0.28). No factor
associated with insuﬃcient fCFZ was identiﬁed. In conclusion, current BMI and TBW cut-offs are poor
indicators of which patients could beneﬁt from increased CFZ dosage regimens.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
A recent survey in the USA reported that surgical site infec-
tions (SSIs) are among the most frequent type (22%) of healthcare-
associated infections [1]. Such infections are associated with
increased healthcare costs, increased risk of hospital re-admission
and increased mortality in the 30-day period following surgery [2].
Obesity, deﬁned as a body mass index (BMI) ≥ 30 kg/m2, is one of
the risk factors for developing these post-operative infections [3–6].
Insuﬃcient serum and tissue concentrations of antibiotics used
for surgical prophylaxis are one of the explanations given for the
increased risk of infection observed in obese individuals. Cefazolin
(CFZ), a hydrophilic, strongly protein-bound (80%), ﬁrst-generation
cephalosporin eliminated primarily by the kidneys is most often the
drug of choice for prophylaxis [7]. Despite an estimated 600 million
obese adults worldwide [8] and a signiﬁcant increase in the number
of obese surgical patients over the past 20 years [9,10], the optimal
prophylactic dose of CFZ for obese individuals has not yet been
established.
Recent guidelines on antibiotic use for surgical prophylaxis
provide some recommendations on CFZ dosage regimens for obese
individuals. However, these recommendations are based on expert
opinion and are supported by limited data showing that the phar-
macokinetics of CFZ is altered in obese patients. Serum and/or tissue
concentrations of CFZ are lower in obese compared with non-
obese patients after administering the same antibiotic dose [11–14].
The French Infectious Diseases Society (SPILF) and the French Society
of Anaesthesia and Resuscitation (SFAR) have, since 2010, recom-
mended an increased dosage regimen of CFZ in heavier patients:
2 g for patients with a BMI < 35 kg/m2 and 4 g for those with a
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BMI ≥ 35 kg/m2 [15]. Since 2013, the Infectious Diseases Society of
America (IDSA) has recommended giving 2 g of CFZ to patients with
a total body weight (TBW) of <120 kg and 3 g to those weighing
≥120 kg. The dose is to be repeated after 4 h if surgery is ongoing
and the patient does not have renal insuﬃciency [7].
Since the publication of these guidelines, only two studies have
evaluated the clinical relevance of these recommendations in non-
pregnant adults. One retrospective clinical study performed in a
cohort of 198 surgical patients concluded that there was little ev-
idence for increasing CFZ dosage regimens in obese patients because
SSI rates were similar in obese and non-obese patients. However,
the studywas underpowered to show any differences and the cohorts
were not stratiﬁed by the recommended cut-offs, as the mean
TBW and BMI values for the two groups were 90 kg vs. 110 kg
and 27 kg/m2 vs. 35 kg/m2, respectively [16]. Another pharmaco-
kinetic (PK) study on CFZ in eight morbidly obese and seven non-
obese individuals conﬁrmed signiﬁcant PK changes inmorbidly obese
patients, attributed to changes in TBW; the authors recommended
using 3 g of CFZ for prophylaxis in morbidly obese patients [17].
However, the optimal BMI or TBW cut-off at which the CFZ dosage
regimen should be increased was not identiﬁed.
The objective of this study was therefore to evaluate whether
the proposed BMI and/or TBW cut-offs could accurately identify
which patients require CFZ dose adjustment for surgical prophylaxis.
2. Patients and methods
2.1. Study design and patient selection
This prospective study was performed at Erasme Hospital, the
academic hospital of the Université Libre de Bruxelles in Brussels,
Belgium. All consecutive, consenting patients undergoing gastric
bypass surgery, partial hepatectomy, duodenopancreatectomy or
colectomy between October 2011 and October 2013 were in-
cluded. These surgical procedures were selected because only
patients who would need central lines during surgery could
be included in the study and, in our institution, central venous
catheters are not inserted for uncomplicated routine surgical in-
terventions. At 30–60 min prior to surgery, all patients receive
a 2 g intravenous (i.v.) dose of CFZ over 30 min for surgical pro-
phylaxis. Patients were excluded from the study if they were
pregnant or lactating, were <18 years old, had a known allergy to
β-lactams, had a serum creatinine level >1.3 mg/dL, had peripher-
al oedema and/or had pre-operative signs of hepatic dysfunction
(total bilirubin levels > 2.5 mg/dL, altered coagulation and/or
albuminaemia < 32 g/L). Patients were excluded from the analysis
if blood loss was >1 L during the sampling period of the study
because signiﬁcant blood loss has been associated with antibiotic
PK changes [7,18].
To ensure a similar distribution of patients of different sizes, pa-
tients were stratiﬁed into different groups of BMI as they were
enrolled: <30 kg/m2, 30–39 kg/m2 and ≥40 kg/m2. Patient enrol-
ment for each group was stopped when a minimum of 10 patients
and a maximum of 30 patients had been included, or when the
2-year study period came to an end. For data analysis, patients were
then categorised into both a BMI group (<35 kg/m2 or ≥35 kg/m2)
and a TBW group (<120 kg or ≥120 kg).
2.2. Data collection
Demographic data and co-morbidities were recorded. Patients
were weighed on the day prior to surgery and their height and ab-
dominal circumferenceweremeasured. The BMIwas calculated using
the following equation: weight (kg)/height (m2) [19]. Blood loss and
volume of ﬂuid administered during the 180 min after the start of
the CFZ infusion were recorded. The occurrence of a SSI (as deﬁned
by the IDSA) [7] in the 30 days following the surgical procedure was
recorded.
2.3. Serum samples during the surgical procedure
A central venous line was placed in all patients after induction
of anaesthesia for surgery. Two blood samples (3 mL) were collect-
ed from the central line into polypropylene Venosafe® VF-054SAS
serum tubes (Terumo, Leuven, Belgium) immediately prior to the
CFZ infusion (T0). One serum sample was collected at each of the
following time points after the start of the CFZ infusion: 30min (T30);
60min (T60); 120min (T120); and 180min (T180). A ﬁnal serum sample
was taken at the end of the surgical procedure, except in patients
undergoing partial hepatectomy. In these patients, sampling was
stopped at T180, before portal triad clamping and resection of the
liver, to limit any potential PK changes associated with this type of
surgery [20].
After each serum sampling, the catheter was purged with 10mL
of physiological serum. Exact sampling timeswere recorded. Samples
were kept on ice and were sent directly to the clinical chemistry
laboratory where they were centrifuged at 3000 rpm at 4 °C for
10 min before the supernatant was removed and then frozen at
−80 °C to be analysed at a later date.
2.4. Measurement of cefazolin serum concentrations
A modiﬁed liquid chromatography–ultraviolet spectrophotom-
etry technique was used to measure CFZ levels [21]. Analyses were
conducted using an ACQUITY UPLC® (ultra performance liquid chro-
matography) system (Waters, Zellik, Belgium). The UPLC separation
was carried out at 50 °C. The mobile phase consisting of acetoni-
trile and phosphate buffer (0.3% phosphate buffer/acetonitrile 98:2
v/v) (pH 5.0) was delivered at a ﬂow rate of 0.6 mL/min. Six-level
aqueous calibrators with concentrations of CFZ ranging from 1mg/L
to 150 mg/L were employed for quantiﬁcation of total CFZ (tCFZ)
and unbound (free) CFZ (fCFZ) serum concentrations. For tCFZ, 50 μL
of the internal standard solution (cefoperazone 200mg/L) was added
to 200 μL of thawed sample, precipitation of serum proteins was
performed by adding 800 μL of methanol, and the mixture was then
vortex-mixed. Following evaporation under nitrogen, the residue
was reconstituted with 300 μL of phosphate buffer and was vortex-
mixed for UPLC analysis. For fCFZ, 500 μL of sample was subjected
to ﬁltration using a Centrifree® device (Merck Millipore, Overijse,
Belgium) by centrifugation (two times at 4000 rpm) for 10 min at
4 °C. The ﬁltrate was mixed with 25 μL of the internal standard so-
lution and was used as such for UPLC analysis. The coeﬃcients of
variation for CFZ were <6.7% for mean concentrations varying from
19.8 mg/L to 102 mg/L.
2.5. Measurement of renal function
Pre-operative serum creatinine levels were recorded. Serum and
urinary creatinineweremeasured using a Hitachi Modular P analyser
based on the Jaffé method [22] on a serum and urine sample (from
a 24-h collect) taken on the day following the surgical interven-
tion. Creatinine clearance (CLCr) was calculated using the following
equation: CLCr,24h (mL/min) = [urine creatinine (mg/dL) × volume
(mL)]/[plasma creatinine concentration on the day of the urine collect
(mg/dL) × 1440 min].
2.6. Free fatty acid and plasma protein determination
Serum albumin, α-1-acid glycoprotein, total proteins and free fatty
acids were measured on the T0 serum sample using a Hitachi
Modular analyser (Roche Diagnostics, Vilvoorde, Belgium) accord-
ing to the manufacturer’s instructions.
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2.7. Estimation of unbound cefazolin serum concentrations at T240
Considering that most of the sampling was performed during
the CFZ elimination phase, the following equation: [lnCt = −ket + lnC0]
was used to determine the terminal elimination rate constant (ke)
and to estimate the serum concentrations of the drug at C0, where
Ct is the measured serum concentration at the speciﬁed time and
C0 is the virtual serum concentration at the beginning of the elim-
ination phase [23]. Estimated serum concentrations of fCFZ and tCFZ
at T240 (when measured samples were not available) were deter-
mined based on extrapolation of the linear logarithmic fCFZ and tCFZ
elimination equation until T240. To validate the extrapolationmethod,
estimated serum concentrations of fCFZwere determined for all mea-
sured fCFZ values during the elimination phase (corresponding to
samples taken from T60 onwards) and were compared. Subgroups
were also compared: serum samples taken at T240; and all serum
samples with a measured fCFZ concentration <12mg/L, correspond-
ing to the serum concentrations most likely to be found at T240.
Graphs of estimated fCFZ values as a function of measured values
were also drawn.
2.8. Pharmacokinetic analyses
PK parameters were calculated using non-compartmental anal-
ysis. The area under the concentration–time curve (AUC) and
the area under the ﬁrst moment curve (AUMC) for fCFZ and tCFZ
plasma proﬁles were calculated using the linear trapezoidal
method andwere extrapolated to inﬁnitywhere AUC0–∞was deﬁned
as AUC0–last + Clast/ke, and AUMC0–∞ was deﬁned as AUMC0–last +
(t × Clast/ke) + Clast/ke2, and Clast corresponds to the lastmeasured fCFZ
or tCFZ serum concentration. The total body clearance (CL) and
apparent volume of distribution (Vd) of fCFZ and tCFZwere then cal-
culated using the following equations: CLfCFZ or tCFZ = total dose of CFZ
administered/AUC0–∞ and Vd,fCFZ or tCFZ = (AUMC × total dose of CFZ
administered)/(AUC0–∞2). Themean residence time (MRT)wasdeﬁned
as AUMC0–∞/AUC0–∞ minus mean infusion time, which was deﬁned
as infusion time/2. The mean elimination rate constant (k) could
then be calculated by k = 1/MRT. The terminal elimination half-life
(t1/2) for fCFZ and tCFZwere then calculated using t1/2 = 0.693/k [24].
2.8.1. Adequacy of unbound cefazolin concentrations
The European Committee on Antimicrobial Susceptibility Testing
(EUCAST) and the Clinical and Laboratory Standards Institute (CLSI)
have deﬁned clinical breakpoints for micro-organisms for differ-
ent antimicrobial therapies by taking into account in vitro and in
vivo pharmacokinetic/pharmacodynamic (PK/PD) data. β-Lactam an-
tibiotics are time-dependent drugs [25], meaning that the PK/PD
parameter that best describes their eﬃcacy is the time that the con-
centration of unbound antibiotic remains above the minimum
inhibitory concentration (MIC) of the bacteria (fT>MIC) [26]. Based
on expert opinion, to deliver appropriate antibiotic therapy for sur-
gical prophylaxis, the dose and timing of antibiotic administration
need to ensure that serum and tissue concentrations remain above
the MIC of the most likely pathogens during the entire surgical pro-
cedure [7]. For digestive surgery, prophylactic antibiotics should be
active against Enterobacteriaceae and Staphylococcus spp. For En-
terobacteriaceae, the clinical breakpoints for CFZ are 1mg/L according
to the CLSI [27], whereas EUCAST no longer reports this value [28].
For methicillin-susceptible Staphylococcus spp., clinical break-
points are 4 mg/L according to the CLSI and EUCAST [27,28]. For the
current study, we therefore deﬁned adequate serum concentra-
tions as fCFZ ≥ 4 mg/L.
Table 1
Characteristics of patients (n = 63) according to body mass index (BMI) and total body weight (TWB).
Characteristic BMI TBW
<35 kg/m2 (n = 20) ≥35 kg/m2 (n = 43) P-value <120 kg (n = 41) ≥120 kg (n = 22) P-value
Age (years) 48 ± 14 44 ± 10 0.11 47 ± 11 43 ± 10 0.14
Male sex 6 (30) 11 (26) 0.71 6 (15) 11 (50) <0.01
Height (m) 1.70 ± 0.09 1.69 ± 0.10 0.72 1.66 ± 0.09 1.74 ± 0.09 <0.01
Abdominal circuference (cm) 103 ± 12 128 ± 13 <0.01 112 ± 14 136 ± 11 <0.01
BMI (kg/m2) 28 ± 5 43 ± 5 <0.01 34 ± 7 46 ± 5 <0.01
TBW (kg) 80 ± 15 122 ± 20 <0.01 92 ± 16 138 ± 11 <0.01
Co-morbidities
Hypertension 2 (10) 9 (21) 0.48 5 (12) 6 (27) 0.17
Diabetes mellitus 1 (5) 6 (14) 0.42 5 (12) 2 (9) 1.00
Neoplasia 8 (40) 1 (2) <0.01 8 (20) 1 (5) 0.14
Surgery
Coelioscopy/laparotomy 10 (50)/10 (50) 42 (98)/1 (2) <0.01 31 (76)/10 (24) 21 (95)/1 (5) 0.08
Surgical intervention
Bypass 8 (40) 43 (100) <0.01 29 (71) 22 (100) 0.01
Partial hepatectomy 6 (30) 0 (0) <0.01 6 (15) 0 (0) 0.08
Other 6 (30) 0 (0) <0.01 6 (15) 0 (0) 0.08
CFZ to end of surgery (min)a 180 (144–270) 120 (105–135) <0.01 135 (120–202) 120 (105–135) 0.01
Blood loss (L)b 0.1 (0–0.4) 0 (0–0) <0.01 0 (0–0.1) 0 (0–0) 0.16
Fluids administered (L)b 2.0 (1.5–2.0) 2.0 (1.3–2.5) 0.65 2.0 (1.5–2.0) 2.0 (1.5–2.5) 0.10
Biological data
Creatinine (mg/dL) 0.7 (0.6–1.0) 0.7 (0.7–0.9) 0.77 0.7 (0.6–0.8) 0.8 (0.7–0.9) 0.11
CLCr,24h (mL/min)c 130 (96–162) 104 (70–153) 0.17 100 (69–147) 130 (95–178) 0.05
Albumin (g/L)d 3.8 (3.6–3.9) 4.1 (3.8–4.4) 0.03 4.0 (3.6–4.4) 4.0 (3.8–4.4) 0.49
Free fatty acids (mg/dL)d 0.76 ± 0.23 0.92 ± 0.23 0.04 0.85 ± 0.23 0.92 ± 0.30 0.32
α-1-Acid glycoprotein (g/L)d 88.8 ± 50.3 90.3 ± 22.0 0.89 87.3 ± 35.7 94.7 ± 24.2 0.45
Total proteins (g/L)d 61.4 ± 12.8 64.8 ± 7.3 0.24 63.0 ± 9.9 65.3 ± 7.9 0.42
CFZ, cefazolin; CLCr,24h, measured creatinine clearance with 24-h urine collection.
Data are presented as counts (%), median (interquartile range) or mean ± standard deviation.
a Time from initiation of CFZ infusion until wound closure.
b Volume of blood loss or ﬂuids administered until 180 min after initiation of the CFZ infusion.
c 24-h urine collects were not collected in 5 patients, so data on CLCr,24h is presented for 58 patients.
d These serum parameters were not measured in 14 patients, so data on albumin, free fatty acids, α-1-acid glycoprotein and total proteins are presented for 49 patients.
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The adequacy of fCFZ serum concentrations at T180 and T240 for
different BMI (<35 kg/m2 and ≥35 kg/m2) and TBW (<120 kg and
≥120 kg) groups was explored.
2.8.2. Factors associated with insuﬃcient serum concentrations of
unbound cefazolin
Possible factors associated with insuﬃcient fCFZ concentra-
tions at T180 and T240 were investigated, including age, sex, BMI, TBW,
abdominal circumference, CLCr,24h, blood loss and quantity of
ﬂuid administered until T180, type of surgery, and serum concen-
trations of albumin, total proteins, α-1-acid glycoprotein and free
fatty acids.
2.8.3. Statistical analysis
Categorical variables are reported as proportions. Continuous
variables with or without normal distribution are reported as the
mean ± standard deviation and median (interquartile range),
respectively. Results from patients with a BMI ≥ 35 kg/m2 were
compared with those from patients with a BMI < 35 kg/m2, and
results from patients weighing ≥120 kg were compared with
those from patients weighing <120 kg. Categorical data were
compared using the χ2 test or Fisher’s exact test as appropriate.
Continuous variables with normal distribution were compared
using Student’s t-test [or analysis of variance (ANOVA) for repeat-
ed measures and post-hoc Bonferroni corrections], and variables
without normal distribution were compared with the Mann–
Whitney test. Receiver operating characteristic (ROC) curve analysis
was performed to test the accuracy of BMI and TBW as proxies for
identifying patients with insuﬃcient fCFZ serum concentrations
at T240. Pearson’s linear correlation coeﬃcient was calculated
when evaluating fCFZ at T240 as a function of TBW and BMI. All
tests were two-sided and P-values of <0.05 were considered sta-
tistically signiﬁcant.
2.8.4. Ethics
The PK study was approved by the Erasme Hospital Ethics Com-
mittee and by the Belgian regulatory agency. Written informed
consent was obtained from all patients.
3. Results
A total of 69 patients were included in this study, of whom 6
patients were eventually excluded (4 because serum samples were
not taken during surgery, 1 because of an unknown pregnancy
Fig. 1. Estimated unbound cefazolin (fCFZ) serum concentrations as a function of measured concentrations: (a) all measured serum samples taken from T60 until the end of
sampling (n = 230 serum samples); (b) all measured samples at T240 (n = 17 serum samples; 17 patients); and (c) all measured samples with fCFZ serum concentration of
<12 mg/L (n = 133 serum samples). Black solid line (y = x). T60, serum sampling taken 60 min after the start of CFZ infusion.
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diagnosed shortly after signing the informed consent and 1 because
ﬁve of the seven serum samples showed marked haemolysis). At
enrolment, the remaining 63 patients were stratiﬁed according to
BMI (<30 kg/m2, 12 patients; 30–39 kg/m2, 21 patients; and ≥40 kg/
m2, 30 patients). For data analysis, patients were categorised
according to BMI (<35 kg/m2, 20 patients; and ≥35 kg/m2, 43 pa-
tients) and TBW (<120 kg, 41 patients; and ≥120 kg, 22 patients).
Twenty-four hour urine collections were not performed in 5 pa-
tients, and some serum parameters were notmeasured in 14 patients
due to insuﬃcient serum.
Patient characteristics, biological parameters and types of surgery
are reported in Table 1. Most patients with a BMI ≥ 35 kg/m2 or with
a TBW ≥ 120 kg underwent laparoscopic gastric bypass surgery and
none underwent partial hepatectomy. Only one post-operative SSI
was reported. Themajority of patients (56/63; 89%) wereWhite Cau-
casians of European origin.
Becausemost of the surgical procedures lasted less than 240min,
serum samples were obtained in just 17 of the 63 patients at this
time point. fCFZ serum concentrations were therefore estimated at
T240 for the remaining patients as explained in Section 2.7. Fig. 1a
shows the estimated fCFZ serum concentrations as a function of mea-
sured concentrations for the patients with measured fCFZ
concentrations taken during the CFZ elimination phase (230 serum
samples taken from T60 onwards); Fig. 1b shows the subgroup of
17 patients with concentrations measured at T240; and Fig. 1c (133
serum samples) shows the subgroup of serum samples with a mea-
sured fCFZ serum concentration of <12 mg/L. The extrapolation
method provided estimated fCFZ values that were not signiﬁ-
cantly different from measured fCFZ serum concentrations in any
of these three groups (P = 0.20, 0.56 and 0.11, respectively). The es-
timated fCFZ concentrations at T240 for patients without measured
serum fCFZ concentrations at this time point were therefore used
for further analysis.
Fig. 2 illustrates fCFZ and tCFZ concentrations over time as a func-
tion of BMI and TBW. Independent of time, mean tCFZ and fCFZ
serum concentrations were signiﬁcantly lower in patients weigh-
ing ≥120 kg than in those weighing <120 kg (P = 0.01 and 0.01,
respectively) but were not signiﬁcantly different in patients with
a BMI ≥ 35 kg/m2 compared with those with a BMI < 35 kg/m2
(P = 0.20 and 0.12, respectively). Furthermore, mean serum con-
centrations of tCFZ and fCFZ decreased signiﬁcantly over time for
both BMI and TBW groups. After post-hoc Bonferroni corrections,
mean tCFZ and fCFZ differed signiﬁcantly between T30, T60, T120 and
T180, but not between T180 and T240.
Table 2 shows PK parameters of tCFZ and fCFZ in all study pa-
tients: the AUC0–180 values were signiﬁcantly smaller and the Vd was
signiﬁcantly greater in patients weighing ≥120 kg compared with
those weighing <120 kg, but no differences were observed in the
different BMI groups.
Fig. 3 shows adequate serum concentrations at T180 in all pa-
tients but in only 40/63 patients (63%) at T240. No statistical differences
were observed between the percentages of patients who had ad-
equate fCFZ concentrations at T240 in the different BMI and TBW
groups.
Fig. 4 shows serum concentrations of fCFZ at T240 as a function
of BMI and TBW. No correlation was observed between BMI and fCFZ
[r = −0.20, 95% conﬁdence interval (CI) −0.43 to 0.05; P = 0.12] and
a weak but signiﬁcant negative correlation was observed between
Fig. 2. Mean total cefazolin (tCFZ) and unbound cefazolin (fCFZ) serum concentrations over time as a function of body size: (a) tCFZ and (b) fCFZ as a function of BMI (<35 kg/
m2 vs. ≥35 kg/m2); and (c) tCFZ and (d) fCFZ as a function of TBW (<120 kg vs. ≥120 kg). Results are presented as the mean ± standard deviation. Dashed horizontal black
line = pharmacodynamic target of adequacy (4 mg/L). *P < 0.05 for the cohort with a TBW ≥ 120 kg compared with the cohort with a TBW < 120 kg. BMI, body mass index;
TBW, total body weight.
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TBW and fCFZ (r = −0.27, 95% CI −0.49 to −0.03; P = 0.03). No obvious
cut-off point for adequate fCFZ serum concentrations could be iden-
tiﬁed for TBW or BMI.
In ROC curve analysis, a test that will not perform any better
than chance will have an AUC value of 0.5. Both BMI and TBW per-
formed poorly for detecting individuals who would beneﬁt from an
increased CFZ dosage regimen, with AUCs of 0.55 (95% CI 0.40–
0.70; P = 0.54) for BMI and 0.57 (95% CI 0.42–0.72; P = 0.36) for TBW.
No factors were identiﬁed that were signiﬁcantly associated with
insuﬃcient fCFZ at T240 (Table 3).
Table 2
Pharmacokinetic (PK) parameters of unbound (free) cefazolin (fCFZ) and total cefazolin (tCFZ) in patients according to body mass index (BMI) and total body weight (TBW).
PK parameters BMI TBW
<35 kg/m2 (n = 20) ≥35 kg/m2 (n = 43) P-value <120 kg (n = 41) ≥120 kg (n = 22) P-value
AUC0–180 (mg · h/L)
tCFZ 306 (266–355) 278 (238–315) 0.08 307 (255–354) 260 (230–280) <0.01
fCFZ 66 (55–80) 58 (51–67) 0.09 62 (55–74) 53 (49–61) 0.01
CL (L/h)
tCFZ 5.1 ± 1.5 5.0 ± 1.1 0.90 5.0 ± 1.4 5.2 ± 1.0 0.50
fCFZ 24.5 ± 5.9 26.9 ± 7.2 0.19 25.1 ± 6.6 28.1 ± 7.1 0.10
Vd (L)
tCFZ 11.9 ± 5.1 12.6 ± 2.9 0.50 11.7 ± 3.9 13.7 ± 3.0 0.04
fCFZ 51.0 ± 20.5 55.5 ± 27.4 0.52 48.6 ± 17.4 64.0 ± 34.1 0.02
t1/2 (h)
tCFZ 1.4 (1.2–1.8) 1.6 (1.3–1.8) 0.25 1.4 (1.2–1.7) 1.7 (1.2–2.1) 0.14
fCFZ 1.1 (1.0–1.6) 1.1 (0.9–1.4) 0.23 1.0 (0.9–1.4) 1.2 (0.9–1.6) 0.40
Data are expressed as the mean ± standard deviation or the median (interquartile range).
AUC0–180, area under the concentration–time curve from 0–180 min; CL, total body clearance; Vd, volume of distribution; t1/2, terminal elimination half-life.
Fig. 3. Percentage of adequate unbound cefazolin (fCFZ) concentrations as a function of (a) timing of serum samples (in all patients at T180 and T240), (b) TBW (<120 kg and
≥120 kg at T240) and (c) BMI (<35 kg/m2 and ≥35 kg/m2 at T240). Dashed horizontal black line = pharmacodynamic target of adequacy (4 mg/L). T180, serum sampling taken
180 min after the start of CFZ infusion; T240, serum sampling taken 240 min after the start of CFZ infusion; TBW, total body weight; BMI, body mass index.
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4. Discussion
In this study, the accuracy of the recommended BMI (≥35 kg/m2)
and weight (≥120 kg) cut-offs proposed by the SPILF, SFAR and IDSA
for increasing the CFZ dosage regimen for surgical prophylaxis was
evaluated in a large cohort of essentially European Caucasian surgi-
cal patients. All patients had adequate serum concentrations at T180
but only two-thirds of patients at T240. Despite a weak negative cor-
relation between TBW and fCFZ serum concentrations at T240, no
signiﬁcant differences in the percentage of patients with adequate
fCFZ concentrations at T240 were observed in the different BMI and
TBW groups. The BMI and TBW cut-offs proposed by the SFAR, SPILF
and IDSA couldnot accurately identifywhichpatients requiredhigher
CFZ dosage regimens to ensure adequate surgical prophylaxis until
T240.Moreover, no factors associatedwith insuﬃcient fCFZ serumcon-
centrations were identiﬁed in this cohort of patients.
This study conﬁrms that 2 g of CFZ provided inadequate surgi-
cal prophylaxis for heavier patients, regardless of the criteria used
(BMI ≥ 35 kg/m2 or TBW ≥ 120 kg), for surgery lasting longer than
180 min. Even among the lighter patients, 2 g of CFZ also provid-
ed inadequate prophylaxis for surgery lasting longer than 180min:
only 75% of patients with a BMI < 35 kg/m2 and 68% of patients
weighing <120 kg had adequate fCFZ serum concentrations at T240.
PK parameters were also only slightly different in the different
TBW groups andwere no different in the various BMI groups. Indeed,
the AUC0–180 was smaller and the Vd was greater in patients weigh-
ing ≥120 kg compared with those weighing <120 kg. These data
conﬁrm observations already made in the literature in which TBW
was identiﬁed as a covariate for the central Vd of CFZ [12,17,29]. We
also found that values of Vd and CL for CFZ in patients weighing
<120 kg and with a BMI < 35 kg/m2 were greater than those re-
ported in the literature in healthy non-obese patients [30–32]. This
relatively large, heterogeneous cohort of patients may have cap-
tured the great variability of CFZ pharmacokinetics in today’s surgical
patients, supporting the notion that ‘no one dose ﬁts all’. Finding
one dose that takes into account all potential factors that may in-
ﬂuence the pharmacokinetics of an antibiotic, such as age, sex, body
size, ethnic origin and more, is indeed diﬃcult.
Fig. 4. Unbound cefazolin (fCFZ) serum concentrations at T240 as a function of (a) body mass index and (b) total body weight. Dashed horizontal black line = pharmacody-
namic target of adequacy (4 mg/L); solid black line = Pearson linear correlation. r, Pearson’s linear correlation coeﬃcient; CI, conﬁdence interval. T240, serum sampling taken
240 min after the start of CFZ infusion.
Table 3
Factors associated with insuﬃcient serum concentrations of unbound (free) cefazolin (fCFZ) in all patients at 240 min after the start of cefazolin infusion.
Variable fCFZ concentration <4 mg/L fCFZ concentration ≥4 mg/L P-value
No. of patients 23 40
Age (years) 43 ± 12 47 ± 11 0.11
Male sex 6 (26) 11 (28) 0.90
TBW (kg) 113 ± 28 106 ± 25 0.24
BMI (kg/m2) 39 ± 9 38 ± 8 0.40
Abdominal circumference (cm) 124 ± 19 (n = 20) 118 ± 17 (n = 35) 0.25
CLCr,24h (mL/min)a 131 (87–164) (n = 20) 105 (75–147) (n = 38) 0.14
Free fatty acids (mg/dL)b 0.86 ± 0.34 (n = 17) 0.89 ± 0.19 (n = 32) 0.72
α-1-Acid glycoprotein (g/L)b 92.6 ± 25.4 (n = 17) 88.2 ± 35.7 (n = 32) 0.65
Albumin (g/L)b 40.0 ± 6.1 (n = 17) 39.2 ± 5.6 (n = 32) 0.64
Total proteins (g/L)b 64.3 ± 8.4 (n = 17) 63.5 ± 9.7 (n = 32) 0.76
Laparoscopy 19 (83) 33 (83) 0.99
Hepatectomy 2 (9) 4 (10) 0.87
Bypass 20 (87) 31 (78) 0.36
Blood lossc 1 (4) 4 (10) 0.44
Fluids administeredd 9 (39) 9 (23) 0.16
TBW, total body weight; BMI, body mass index; n, total number of patients for whom results were available; CLCr,24h, creatinine clearance measured with 24-h urine collects.
Data are presented as counts (percentage), median (interquartile range) or mean ± standard deviation.
a 24-h urine collects were not collected in 5 patients, so data on CLCr,24h are presented for 58 patients.
b These serum parameters were not measured in 14 patients, so data on albumin, free fatty acids, α-1-acid glycoprotein and total proteins are presented for 49 patients.
c Blood loss >500 mL at 180 min after initiation of the cefazolin infusion.
d Volume of ﬂuids administered >2500 mL at 180 min after initiation of the cefazolin infusion.
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With only one SSI in this cohort, no conclusions could be made
regarding the clinical impact of inadequate fCFZ serum concentra-
tions. The only randomised controlled trials found in the literature
comparing 2 g versus 3 g [33–35] or 4 g [36] of CFZ were con-
ducted in obese patients undergoing caesarean sections, showing
no clinical beneﬁt for the higher dosage regimens despite signiﬁ-
cantly higher serum and tissue concentrations of CFZ [33–36].
This study has some limitations. First, the patient cohort was not
extremely obese. However, the patient population was represen-
tative of the obese population in European countries and was heavy
enough to test the recommended BMI and TBW cut-offs. Second,
different patients in the cohort underwent different types of surgery,
possibly inﬂuencing the pharmacokinetics of CFZ, independent of
body size. However, current recommendations on CFZ dosing for
surgical prophylaxis do not make distinctions between types of
surgery, except when extracorporeal circulation is planned [7], and
most patients in this cohort underwent minimally invasive surgery
with minimal blood loss. Third, serum sampling was short and in-
adequacy of fCFZ was only observed at T240, when most fCFZ values
were estimated and not measured, therefore limiting the capacity
to make robust conclusions regarding inadequate dosing. Fourth,
use of the trapezoidal method in the PK analysis may have over-
estimated the AUC of CFZ. Fifth, despite a cohort of 63 patients, the
sample size may still have been too small to detect signiﬁcant
changes in population groups. Finally, we did not measure tissue
concentrations of CFZ, but only fCFZ serum concentrations.
In conclusion, this study has shown that 2 g of i.v. CFZ is insuf-
ﬁcient to ensure adequate fCFZ concentrations for a large proportion
of Caucasian European patients undergoing surgery lasting longer
than 180min. We need to ﬁnd better predictors than BMI and TBW
to identify which patients would beneﬁt from an increased or modi-
ﬁed CFZ dosage regimen to ensure adequate surgical prophylaxis.
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